Bachem (SIX: BANB) informed today about the planned change in the Board of Directors of Bachem Holding AG at the next Annual General Meeting on April 28, 2021.
After 11 years of service on the Board of Directors, Dr Jürgen Brokatzky-Geiger has decided not to stand for re-election at the 2021 Annual General Meeting. Dr Thomas Früh, who has worked for Bachem for more than 20 years, is not available for reelection for health reasons. The Board of Directors will propose Dr Alex Fässler, former member of the Executive Committee of Bachem, for election at the Annual General Meeting in 2021.
Kuno Sommer, Ph.D., Chairman Bachem Holding AG:
“On behalf of the Board of Directors, I would like to express my sincere thanks to Jürgen Brokatzky-Geiger and Thomas Früh for their great commitment and many valuable contributions to our company. I am very pleased that with Alex Fässler we have been able to propose a long-standing expert of our company for election to the Board of Directors. Alex will stand for continuity in the strategic management of the Bachem Group.”
Dr Alex Fässler began his industrial career at Ciba-Geigy, later Novartis, where he held various positions in preclinical Research in Basel, New Jersey and England. He joined Bachem AG in 1998, and thereafter served as Head of Production in the US subsidiary, site manager and finally as regional COO for the Americas. After his return to Switzerland in 2013 he was appointed COO of Bachem Europe, and from 2017 to 2018 he held the function of COO of the Bachem Group and was a member of the Corporate Executive Committee.